What changed
$BJ — AVOID 📊 | 6 MONTHS THESIS
🧭 Conviction: HIGH
🎯 FQ1 FY2027 (ends Apr) | reported May 22 | Rev $5.7B | EPS $1.10 vs $1.03 🟢 | Margin 3.7%
💡 Consensus expected $1.03, actual $1.10, but this beat is not indicative of a turnaround. The underlying business shows flat revenue, declining EPS, and negative FCF. The stock's high P/E reflects expectations of a recovery or premium brand, but the fundamentals don't support it.
🏢 Business Quality: 3/10
📊 Valuation: rich: P/E 20.2x vs peer band 8.6x-14.8x-23.6x, base 14.8x; reverse DCF implies 2.1% FCF growth despite actual negative FCF; multiple methods indicate...
🔮 Catalyst: Q earnings report
⚖️ Avoid BJ as a long — the stock is overvalued at 20.2x earnings with no growth and negative free cash flow, offering a poor reward/risk setup.